Hairy cell leukaemia variant (HCL-V) is a distinct subtype with a characteristic laboratory and immunophenotypic profile that sets it apart from classical HCL. Recognising these features is essential for selecting the appropriate management approach.
This protocol applies to hairy cell leukaemia variant (HCL-V) typically presenting with high lymphocyte counts (lymphocytosis), nucleolated cells lacking monocytopaenia, a CD25-negative immunophenotype, and absence of the BRAF V600E mutation.
In refractory HCL-V, the management approach may include a form of hematopoietic cell transplantation. Full details — including eligibility criteria, the distinction between autologous and allogeneic approaches, sequencing, and all decision points — are available in the complete structured protocol.
See the full regimen below ↓